AMPLY Discovery is revolutionizing the drug discovery process by integrating artificial intelligence (AI) with natural biological diversity. The company leverages next-generation sequencing technology to digitize various forms of life, allowing for the analysis of a vast array of potential medicinal compounds. This innovative approach enables the identification of novel drugs through a high-throughput method, likened to having a billion virtual petri dishes. The digital discoveries are then bio-printed into tangible molecules, which are subjected to rigorous testing in leading hospital laboratories against real diseases, ensuring that the compounds are not only theoretical but also practical and effective.

The AMPLY platform, known as AMPLYfolio AI, is designed to process diverse biological data types, including genomic and transcriptomic information. It employs advanced machine learning techniques to uncover novel compounds by analyzing complex datasets with thousands of metadata tags. Additionally, the platform features a "stock picking" dashboard that allows users to select promising compounds based on predictive analytics. The bioprinting technology connects digital discoveries to high-throughput synthesis methods, facilitating the rapid creation and validation of new drugs. This comprehensive pipeline ensures that each compound undergoes thorough evaluation for efficacy and safety, addressing critical health challenges such as drug-resistant infections.

United Kingdom

AMPLY Discovery is a Belfast-based techbio company that deploys machine learning and synthetic biology to mine vast biological data to discover novel drug and nutraceutical candidates. Their technology digitizes life's diversity, using next-gen sequencing for drug discovery to tackle complex diseases such as cancer, metabolic disease, and infectious diseases through AI (artificial intelligence). They have raised over €1.6 million in grant funding from Innovate UK to develop their drug discovery platform.

AMPLY Discovery

Company Details